NYSE:PFEPharmaceuticals
Pfizer Reshapes Pipeline With Novavax Deal And ViiV Exit
Pfizer (NYSE:PFE) has signed a licensing agreement with Novavax for non-exclusive global rights to use Matrix-M adjuvant technology in vaccines for up to two infectious diseases.
Pfizer is exiting its stake in the ViiV Healthcare joint venture, reshaping its involvement in the HIV treatment market.
These moves reflect a shift in Pfizer's partnerships and pipeline focus as it responds to post-pandemic demand and upcoming patent expirations.
Pfizer, trading at around $26.5, is adjusting its...